Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 25 | 3,512 | 45% |
| 2020 | 17 | 2,576 | 51% |
| 2021 | 16 |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 75% of the cases CMS names in Michigan; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.61.0× | 6% | 4,480 in 2030−0.8%/yr |
| BPH procedures |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
| 2024 |
| 2,577 |
| 66% |
| 2025 est. | ≈ 2,510 | – |
| 2026 est. | ≈ 2,540 | – |
| 2,737 |
| 55% |
| 2022 | 19 | 2,906 | 59% |
| 2023 | 17 | 2,764 | 63% |
| 2024 | 15 | 2,577 | 66% |
| 2025 from claims | – | 2,510 2,303–2,656 | 67% |
| 2026 forecast | – | 2,543 2,238–2,935 | 67% |
| 2027 forecast | – | 2,549 2,179–3,037 | 68% |
| 2028 forecast | – | 2,552 2,129–3,125 | 69% |
| 2029 forecast | – | 2,554 2,086–3,203 | 70% |
| 2030 forecast | – | 2,555 2,047–3,274 | 70% |
In 2025, 4% inpatient hospital, 85% hospital outpatient, 2% surgery center, 9% office.
| −0.8%/yr |
| 3.1 |
| 7% |
| 3,530 in 2030+2%/yr |
| Indiana | 18 | 2,015−2.6%/yr | −2.6%/yr | 3.1 | 13% | 2,050 in 2030+0.2%/yr |
| Missouri | 13 | 1,625−3.4%/yr | −3.4%/yr | 2.9 | 10% | 1,650 in 2030+0.2%/yr |
| Wisconsin | 12 | 1,602−0.7%/yr | −0.7%/yr | 3.1 | 7% | 1,910 in 2030+3%/yr |
| Minnesota | 18 | 1,547−1%/yr | −1%/yr | 3.8 | 9% | 2,280 in 2030+6.7%/yr |
| Iowa | 12 | 908−1.5%/yr | −1.5%/yr | 2.2 | 11% | 880 in 2030−0.4%/yr |
| Kansas | 14 | 868−1.5%/yr | −1.5%/yr | 2.3 | 11% | 890 in 2030+0.4%/yr |
| Nebraska | 4 | 529−3.8%/yr | −3.8%/yr | 2.2 | 9% | 650 in 2030+3.6%/yr |
| South Dakota | 2 | 342−0.3%/yr | −0.3%/yr | 2.8 | 0% | 380 in 2030+1.9%/yr |
| North Dakota | 1 | 216−1.3%/yr | −1.3%/yr | 2.3 | 10% | 220 in 2030+0.5%/yr |
| 40 |
| 3,700−3.6%/yr |
| −3.6%/yr |
| 4.30.9× |
| 29% |
| 3,320 in 2030−1.8%/yr |
| Incontinence, prolapse & sacral neuromodulation | 25 | 1,789−6.7%/yr | −6.7%/yr | 2.10.9× | 4% | 1,480 in 2030−3.1%/yr |
| Prostatectomy & nephrectomy | 10 | 897−4.5%/yr | −4.5%/yr | 1.20.8× | 0% | 1,150 in 2030+4.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Hologic Sales And Service leads with 67% of company spending on these surgeons in 2025, +26 pts on 2024.
In 2025, 9 companies reported engagement with Michigan’s surgeons worth $57K in consulting, speaking, meals and travel tied to these products, about $3,773 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.